- With Organon shares trading at around US$6.05, this article walks through the key signals to help you assess whether they appear to be a value opportunity or a value trap.
- The stock has been under pressure, with a 7 day return showing a 3.5% decline, a 30 day return showing a 25.7% decline, and a 1 year return showing a 58.0% decline, which can influence how the market is pricing its risks and potential.
- Recent coverage has focused on Organon as a stand alone women's health and biosimilars business after its separation from Merck, highlighting questions about its product portfolio, competitive position, and debt load. These themes help frame whether recent share price weakness reflects short term sentiment or longer term concerns about the underlying business.
- Even so, Organon currently scores a 5 out of 6 valuation check. This sets up a closer look at how different valuation methods assess the stock and, later in the article, a broader way to think about what that score may mean for you.
Find out why Organon's -58.0% return over the last year is lagging behind its peers.
Approach 1: Organon Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today using a required rate of return.
For Organon, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $394.5 million, and analysts plus extrapolated estimates point to projected Free Cash Flow of $1,346 million in 2030, with a series of annual projections in between that are discounted back to today. All figures are in US$.
Bringing all those discounted cash flows together gives an estimated intrinsic value of about $58.54 per share, using Organon’s cash flow projections as the input. Against a current share price of around $6.05, the DCF output implies the shares are about 89.7% undervalued, according to this specific model and its assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Organon is undervalued by 89.7%. Track this in your watchlist or portfolio, or discover 61 more high quality undervalued stocks.
Approach 2: Organon Price vs Earnings
For a company that is generating earnings, the P/E ratio is a commonly used way to check how much you are paying for each dollar of profit. It is simple to interpret and lets you line up one stock against its sector or the wider market using the same yardstick.
What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower expected growth or higher risk usually point to a lower P/E.
Organon currently trades on a P/E of about 8.42x. That sits below the Pharmaceuticals industry average of about 16.88x and also below the peer group average of around 13.21x. Simply Wall St’s Fair Ratio for Organon is 23.86x, which is its proprietary estimate of what a suitable P/E might be after considering factors such as earnings growth, profit margins, industry, market cap and risk.
The Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for those company specific drivers instead of assuming every business should trade on the same multiple. On this basis, Organon’s current P/E of 8.42x sits well below the Fair Ratio of 23.86x, which indicates that the shares may be undervalued on this metric.
Result: UNDERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Organon Narrative
Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple way for you to attach a clear story about Organon to the numbers you see, by linking your view on future revenue, earnings and margins to a Fair Value that can then be compared with the current price.
On Simply Wall St’s Community page, Narratives are set up as easy, guided forecasts, so you can see how a cautious view that lines up with a Fair Value of US$5 or a more optimistic view that lines up with US$12 flows through to different assumptions on revenue, profit margins, future P/E and discount rates, and then decide how that compares with the current Organon share price.
Because Narratives update when new information such as news, M&A interest, guidance or earnings arrives, they provide a living reference point that connects Organon’s evolving story to a financial model and Fair Value range. This can help you decide whether the gap between your Fair Value and today’s price looks large enough to consider buying, selling, or simply watching.
For Organon, however, we will make it really easy for you with previews of two leading Organon narratives:
Fair value in this bullish narrative: US$9.00 per share
Implied discount to this fair value versus the current US$6.05 share price: about 33% undervalued
Revenue growth assumption: 71.06%
- Analysts in this camp see new product launches, growing biosimilar adoption and a shift toward higher margin assets as key supports for earnings over time.
- They build in revenue of about US$6.5b and earnings of US$990.3m by 2028, with profit margins rising and a future P/E of 4.7x on those earnings.
- This view accepts that policy risk, reliance on legacy products and restructuring costs remain real hurdles, so the upside case still depends on solid execution and disciplined capital allocation.
Fair value in this bearish narrative: US$5.00 per share
Implied premium to this fair value versus the current US$6.05 share price: about 21% overvalued
Revenue growth assumption: 7.83%
- Bearish analysts focus on pricing pressure, loss of exclusivity, a thinner pipeline and a heavy debt load as constraints on future revenues and margins.
- Their model works off largely flat revenues around US$6.2b and earnings of US$900.6m by 2029, but with the shares only warranting a 2.0x P/E given these risks.
- This view treats Organon as a company that may improve operationally yet still struggle to justify a higher valuation if competition, regulation and funding costs stay challenging.
Do you think there's more to the story for Organon? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com